Saturday, September 27 | Sunday, September 28 |
Monday, September 29


(Program as of August 2014)

Friday, September 26

11:00 am Registration is Open
(Viger Foyer)
1:30–6:00 pm Poster Set up
(Viger Hall)
1:30 pm Ballroom is Open
(All sessions to be held in Ballroom)
3:00-3:10 pm Introductory Remarks
3:10-4:00 pm Keynote Address
Kenneth Fearon, MD, MBBch. Hons.
Professor of Surgical Oncology
University of Edinburgh
United Kingdom
  Session 1
Diagnostics and Biomarkers in Cancer Cachexia
  (Chair: Daniel Marks, MD, PhD)
4:15-4:45 pm Body Composition and Prognostication in Cancer
Vickie Baracos, PhD
Professor and Alberta Cancer Foundation Chair in Palliative Medicine
Department of Oncology
University of Alberta
Edmonton Alberta, Canada
4:45-5:15 pm Myostatin as a Marker of Cachexia in Gastric Cancer
Maurizio Muscaritoli, PhD
Professor Department of Clinical Medicine Sapienza, University of Rome
Rome, Italy
5:15-5:45 pm Cutting Edge Science in Cancer Cachexia
(5 min teaser presentations from posters)
  Role of Activin A in Human Cancer Cachexia (ACTICA study)
Jean Paul Thissen, PhD (Brussels, Belgium)
  Human Cancer Cachexia Pathways: Implications of Muscle Ageing?
Carson Jacobi, PhD (Novartis, Basel, Switzerland)
  Prehabilitation vs Rehabilitation: A Randomized Control Trial in Patients Undergoing Colorectal Resection for Cancer
Rashami Awasthi (Concordia University, Montreal, Canada)
  NEO1940: A Novel Cannabinoid Receptor Agonist with Reduced Brain Exposure as a Multimodal Supportive Care Therapy in Cancer Patients with Anorexia and Weight Loss
Sultan Ahmad, PhD (NEOMED Institute, Montréal, Canada)
  Cachexia Evolution in Renal Cell Carcinoma Patients and its Relation with Cardiac Ejection Fraction Evaluated by MUGA Scan
Seyyed Mohammad Reza Kazemi-Bajestani (University of Alberta, Alberta, Canada)
6:00-8:00 pm Welcoming Reception
(Salon Maisonneuve ABC – 36th floor)
8:00–10:00 pm Poster Viewing (Viger Hall)
Coffee & dessert (Viger Foyer)

Back to top ...

Saturday, September 27

6:30-8:00 am Breakfast
(Salon Maisonneuve ABC – 36th floor)
  Session 2
Mechanisms of Muscle Wasting in Cancer Cachexia:
Part I
  (Chair: Teresa Zimmers, PhD)
8:00-8:30 am The Role of p38beta MAPK in Cachexia
Yi-Ping Li, PhD
Associate Professor
Department of Integrative Biology and Pharmacology
University of Texas Health Science Center
Houston, Texas, USA
8:30-9:00 am Uncovering IL-6-independent mechanisms involved in STAT3-induced Cachexia
Imed Gallouzi, PhD
Biochemistry Department & Goodman Cancer Center
McGill University
Montreal, Quebec, Canada
9:00-9:15 am BMP Axis in Experimental Cancer Cachexia
Roberta Sartori, PhD
Venetian Institute of Molecular Medicine
Padova, Italy
9:15-9:30 am Exploring New Targets within the TGFβ Signaling Network as Interventions for Cachexia
Paul Gregorevic, PhD
Laboratory Head
Baker IDI Heart and Diabetes Institute
Melbourne, Australia
9:30-9:45 am Myofilament protein content and muscle function in cancer patients
Michael Toth, PhD
Department of Medicine
University of Vermont College of Medicine
Burlington, Vermont, USA
9:45-10:15 am Coffee Break
(Viger Foyer)
10:15-10:45 am Myostatin Function in Cancer Cachexia
Mridula Sharma, PhD
Associate Professor
Department of Biochemistry, National University of Singapore
10:45-11:15 am Cytokine Regulation of Muscle Wasting in Cachexia
Josep Argilés, PhD
University of Barcelona, Department of Biochemistry and Molecular Biology
Barcelona, Spain
11:15-11:30 am Role of the USP19 deubiquitylating enzyme in muscle wasting and myogenesis
Simon S. Wing, MD
McGill University
Montreal, Quebec, Canada
11:30-12:00 pm Cutting Edge Science in Cancer Cachexia
(5 min teaser presentations from posters)
  Persistent C/EBPβ Expression in Muscle Satellite Cells Contributes to the Pathogenesis of Cancer Cachexia
Nadine Wiper-Bergeron, PhD (University of Ottawa, Ottawa, Canada)
  Inhibition of FoxO Prevents Cancer-Induced Diaphragm Atrophy and Inhibits Cardiac Pathology
Andrew Judge, PhD (University of Florida, Gainesville, USA)
What is the impact of AMPK activation on cytokine-induced muscle atrophy?
Derek Hall (McGill University, Montreal, Canada)
  Inhibition of JAK/STAT3 Pathway with Ruxolitinib and Tofacitinib Does Not Block Skeletal Muscle Atrophy in C-26 Cancer Cachexia Model
Tianshun Xu, PhD (GlaxoSmithKline, Durham, USA)
12:00-1:30 pm Lunch
(Salon Maisonneuve ABC – 36th floor)
  Session 3
Cachexia Promoters from Outside the Myofiber
  (Chair: Maurizio Muscaritoli, PhD)
1:30-2:00 pm Neuroendocrine influences in Cachexia
Daniel Marks, MD, PhD
Professor, Pediatric Endocrinology
Credit Union for Kids Professor in Pediatric Research
Oregon Health & Science University
Portland, Oregon, USA
2:00-2:30 pm The Role of the Muscle Stem Cell Niche in Regulating Regenerative Myogenesis
Michael Rudnicki, OC, PhD, FRSC
Professor, Department of Medicine, University of Ottawa
Senior Scientist & Director Regenerative Medicine Program
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
2:30-2:45 pm Tumor-derived GM-CSF Enhances Cancer-Associated Cachexia by Promoting Increased Adipocyte Lipolysis
Aaron Laine, MD, PhD
Resident Radiation Oncology
UT Southwestern Medical Center
Dallas, Texas, USA
2:45-3:00 pm Cancer-Associated Cachexia: A switch from White to Brown Fat due to systemic inflammation leads to organ wasting
Erwin Wagner, PhD
BBVA Foundation-CNIO Cancer Cell Biology Program
Madrid, Spain
3:00-3:15 pm Muscle Wasting and Impaired Myogenesis in Cachexia
Paola Costelli, PhD
Department of Clinical and Biological Science
University of Torino
Torino, Italy
3:15-3:45 pm Coffee Break
(Viger Foyer)
3:45-4:15 pm SOCS3 is a bi-functional buffer of muscle growth and wasting
Teresa Zimmers, PhD
Associate Professor,
Department of Surgery
IU Simon Cancer Center
Indiana University, School of Medicine
Indianapolis, Indiana, USA
4:15-4:45 pm Cachexia and the Role of the Muscle Microenvironment
Denis Guttridge, PhD
Professor, Department of Molecular Virology, Immunology and Medical Genetics
The Ohio State University
Columbus, Ohio, USA
4:45-5:00 pm Cancer derived MIC-1/GDF15 induced starvation leads to Cachexia
Samuel Breit, PhD
St Vincent's Hospital
Sydney, Australia
5:00-7:00 pm Poster Viewing (Judging)
(Viger Hall)
7:45 pm Gala Dinner – Café Caf Conc' Theatre

A Tribute to Neil MacDonald, MD and Special Presentation
"Palliative Rehabilitation Program Improves Patient Functioning"

Research Consultant
Bruyere Research Institute
Ottawa, Ontario, Canada

Back to top ...

Sunday, September 28

6:30-8:00 am Breakfast     
(Salon Maisonneuve ABC – 36th floor)
  Session 4
Mechanisms of Muscle Wasting in Cancer Cachexia:
Part II
  (Chair: Josep Argilés, PhD)
8:00-8:30 am Ghrelin action in Cachexia
Andrea Graziani, PhD
Department of Translational Medicine
University of Piemonte Orientale
Novara, Italy
8:30-9:00 am Signaling Pathways that Regulate Skeletal Muscle Atrophy and Hypertrophy
David Glass, MD
Novartis Institutes for Biomedical Research
Cambridge, Massachusetts, USA
9:00-9:30 am Stress, inflammation and cachexia: role of physical activity
Dario Coletti, PhD
Assistant Professor
University Pierre et Marie Curie Paris 06
Paris, France
9:30-10:00 am Thermogenesis and Altered lipid Metabolism in Cancer Cachexia Graham Robertson, PhD
Senior Scientist
Tumorkine Group, The Kinghorn Cancer Centre Garvan Institute of Medical Research
Sydney, Australia
10:00-10:30 am Announce Poster Winners; Coffee Break
(Viger Foyer)
10:30-10:45 am TGF-β Mediates Muscle Weakness in Bone Metastases via Oxidation-Induced Calcium Leak
David L. Waning, PhD
Assistant Research Professor
Indiana University Indianapolis,
Indiana, USA
10:45-11:00 am T Cell Function in Diabetes and Cancer-Associated Cachexia
Joanna Davies, PhD
President and CEO
San Diego Biomedical Research Institute
San Diego, California, USA
11:00-11:30 am IL-6 and Mitochondrial Dysfunction in Cachexia
James Carson, PhD
Department of Exercise Science
University of South Carolina
Columbia, South Carolina, USA
11:30-12:00 pm Molecular Signatures of Cancer Cachexia
Michel Tremblay, PhD
Department of Biochemistry / Goodman Cancer Center
McGill University
Montreal, Quebec, Canada
12:00-1:30 pm Lunch & Poster Pick up
(Salon Maisonneuve ABC – 36th floor)
  Session 5
Pre-Clinical to Clinical Studies
  (Chair: Vickie Baracos, PhD)
1:30-2:00 pm Metabolic Rearrangement in Cancer Cachexia
Marion Couch, MD, PhD
Professor, Chair OHNS Department
Indiana University School of Medicine
Indianapolis, Indiana, USA
2:00-2:30 pm Malignant Inflammation and its Role in Disease Progression and HPA Mediated Cancer Symptoms
Michael Stecher MD
Medical Director
XBiotech USA
Austin, Texas, USA
2:30-3:00 pm Emerging Approaches to Treating Muscle Atrophy and Weakness
Mohamed El Mouelhi, MD, PhD, FACP
Executive Director
Translational Medicine,
Musculoskeletal Novartis Institutes for Biomedical Research East Hanover, NJ, USA
3:00-3:15 pm HDAC Inhibition as a Therapeutic Strategy for Cancer Cachexia
Ching-Shih Chen, PhD
Professor of Medicinal Chemistry
College of Pharmacy and Comprehensive Cancer Center
Ohio State University
Columbus, Ohio, USA
Institute of Biological Chemistry, Academia Sinica
Taipei, Taiwan
3:15-3:45 pm Coffee Break
(Viger Foyer)
3:45-4:15 pm Targeting GDF15 with the inhibitory antibody AV-380 for the treatment of Cancer Cachexia
Lorena Lerner, PhD
AVEO Oncology Inc.
Cambridge, Massachusetts, USA
4:15-4:30 pm Next Generation Sequencing of the Muscle and Fat Transcriptome in Patients with Cancer Cachexia Reveals Novel Mechanisms
Amal H.I. Al Haddad, RN, BSN, MSHRM
PhD candidate - Cancer Biology Tract, Prof. Thomas E. Adrian Lab
Department of Physiology, College of Medicine
United Arab Emirates University
Al Ain, United Arab Emirates
4:30-4:45 pm Baseline Characteristics of Anamorelin Phase III Clinical Trial program (ROMANA), a novel Treatment for Anorexia-Cachexia in Non-Small Cell Lung Cancer (NSCLC) Patients
Speaker for Helsinn
4:45-5:15 pm Ghrelin Therapy in Cancer Cachexia
Jose M. Garcia, MD, PhD
Assistant Professor
Departments of Medicine and Molecular and Cell Biology
Baylor College of Medicine
Houston, Texas, USA
5:15pm Closing Remarks

Back to top ...

Monday, September 29 – Departure

Back to top ...